Visus Therapeutics Appoints Ophthalmologist Donnenfeld to Board of Directors
13 January 2023 - - US-based biopharmaceutical company Visus Therapeutics Inc has appointed Eric D. Donnenfeld, M.D., to the company's board of directors, the company said.

Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and cataract surgery and is one of the leading refractive and cataract surgeons in the United States.

Dr. Donnenfeld is the founding partner of Ophthalmic Consultants of Long Island and Ophthalmic Consultants of Connecticut.

He has authored more than 210 papers on the cornea, external disease, cataracts, and refractive surgery, 500 scientific articles, and 50 books and book chapters on a range of subjects pertaining to corneal transplants, cataract care, and laser vision correction.

Dr. Donnenfeld is on the editorial board of nine journals and has participated in over 40 FDA studies. He is one of the first 5 people in the world to perform both laser vision correction and laser cataract surgery.

Dr. Donnenfeld is a Fellow of the American Academy of Ophthalmology and has received its Honor Award, Senior Honor Award, Life Achievement Honor Award, and Secretariat Award.

He is past president of the American Society of Cataract and Refractive Surgery, president-elect of the International Intraocular Implant Society, and Editor in Chief of EyeWorld. He was named #1 on Newsweek's America's Best Eye Doctors list in 2022 and 2021.

In addition, Cataract & Refractive Surgery Today recognized Dr. Donnenfeld as one of the Top 50 Most Influential Ophthalmologists in the United States; The Ophthalmologist named Dr. Donnenfeld to their Power List in 2022, 2020 and 2018; and he was also selected as Ophthalmology Management's 25 Leaders in Innovation.

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye.

The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia.

In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration.